The Emerging Past Director's Cut 2017 Hela Filmen På Svenska

SynAct Pharma Forum Placera - Avanza

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell. Born: 1950 Title: Member of the Board since 2018..

Uli hacksell action pharma

Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. The nomination committee proposes that he is elected as Board Member of the company and that Uli Hacksell is elected new Chairman of the Board. Yilmaz Mahshid has tendered his resignation for personal reasons. Yilmaz Mahshid will remain as CEO until the Annual General Meeting 2021, which takes place on … Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects.

Kristina Luthman Göteborgs universitet

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery.

Biophausia ab - ferroconcrete.puranet.site

Professor Hacksell and Mr Wiklund together Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors.

Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag.
Irene sokolowski obituary

Yilmaz Mahshid will remain as CEO until the Annual General Meeting 2021, which takes place on … Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two.

Notice of extraordinary shareholders' meeting in SynAct Pharma AB. 2020-10-20 · Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. candidate drugs all the way to approved pharmaceuticals with large therapeutic benefit and mechanism of action, as both MIV-818 and. MV-828 are 1) Uli Hacksell took over as CEO on October 15, 2018. 2) Christine Lind Journal of Medicinal and Pharmaceutical Chemistry, 1520-4804 Selective mode of action of guanidine-containing non-peptides at human NPFF receptors Mark R. Brann & Uli Hacksell, 2002 Oct 9, In: Journal of Medicinal Chemistry.
Mall for faktura

lediga heltidsjobb stockholm
deltidsjobb kundtjänst
den osynliga handen
jessica sjöblom limhamn
ja que
vad innebar medicinsk fotvard

ThinkPad T15 Gen 2 15" Intel

För närvarande har Uli Hacksell inga aktier i Synact Pharma. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

Julgran norrtalje
glömt lösenkod för begränsningar

Svensk farmacihistorisk - PerBos Farmacihistoriska Sidor

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Uli Hacksell.